Brief: Surface Oncology Announces Exclusive License Agreement With Gsk For Novel Immunotherapy Program
17/12/2020 11:57
Dec 17 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY ANNOUNCES EXCLUSIVE LICENSE AGREEMENT
WITH GSK
FOR NOVEL IMMUNOTHERAPY PROGRAM
* SURFACE ONCOLOGY INC - TO RECEIVE $85 MILLION UPFRONT
PAYMENT
* SURFACE ONCOLOGY - GSK WILL HAVE EXCLUSIVE RIGHTS TO
DEVELOP AND
COMMERCIALIZE SRF813, A NOVEL ANTIBODY TARGETING PVRIG
* SURFACE ONCOLOGY INC - GSK TO EXCLUSIVELY LICENSE
WORLDWIDE
DEVELOPMENT AND COMMERCIAL RIGHTS TO SURFACE ONCOLOGY'S
PRECLINICAL PROGRAM SRF813
* SURFACE ONCOLOGY - SURFACE ONCOLOGY MAY RECEIVE UP TO AN
ADDITIONAL $730 MILLION IN FUTURE MILESTONE PAYMENTS
* SURFACE ONCOLOGY - PROJECTS CASH RUNWAY SUFFICIENT TO FUND
ITS
OPERATIONS THROUGH 2023
Source text for Eikon: ID:nGNX9zX8lQ
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing